RE:AGM on February 3, 2023The J&J option expires at the end of Jan. and when the calander turns to Feb. Biodexa could be listed on NASDAQ. xB3 could be validated by the largest healthcare company in the world. The Hunter preclinical results in Q2 and Chiesi's European and FDA approval in the first half of 2023 making Chiesi a strategic player in LSDs. Biodexa will have a strategic place in LSDs and be of increased strategic importance to Chiesi as Chiesi has made LSDs a strategic area of interest. As industry rushes to treat the brain Biodexa has a strategic position. With the clinical trial infrastructure and scale of Biodexa and the xB3 validation at this time what could a second deal with Chiesi be worth given the increased strategic importance of Biodexa to Chiesi? The rush is on - they have to move quick. Will Chiesi finally initiate an xB3 clinical trial? An Oxyrane deal adding Gaucher's? Gaucher's is the largest LSD market and Hunter is also a larger market. Biodexa is willing to go head-to-head against Denali. Chiesi could have the standard-of-care for Fabry. Then a cancer deal. Then a Q-Sphera deal with J&J. The validation from J&J and Chiesi and increased credibility of Biodexa leads to an acceleration in xB3 and Q-Sphera deals. There's more too but when you post about the largest opportunity set in the industry for this size of company it keeps going and going...
Is 2023 the year of Biodexa?
And if the central banks start cutting rates because of recession - biotech loves falling rates..